The U.S. Food and Drug Administration (FDA) approved Auvelity (dextromethorphan-bupropion) in August 2023 for the treatment of major depressive disorder (MDD) in adults [1]. As of 2024, Auvelity is an approved medication available for patients in the United States.
What is Auvelity used for?
Auvelity is prescribed to adults diagnosed with major depressive disorder (MDD) [1]. It is intended to treat the symptoms of depression [1].
How does Auvelity work?
The medication is a combination of dextromethorphan and bupropion. Dextromethorphan acts as an NMDA receptor antagonist and a sigma-1 receptor agonist [1]. Bupropion inhibits the reuptake of dopamine and norepinephrine [1]. The precise mechanism by which the combination of dextromethorphan and bupropion exerts its antidepressant effect is not fully understood [1].
When did Auvelity receive FDA approval?
The FDA granted approval for Auvelity on August 19, 2023 [1].
What is the patent status for Auvelity?
Information regarding the specific patent exclusivity for Auvelity can be found on DrugPatentWatch.com [2]. Patents are crucial for determining how long a drug will have market exclusivity before generic versions can be introduced.
Are there any alternatives to Auvelity for depression?
Numerous other medications are available for the treatment of major depressive disorder. These include various classes of antidepressants such as selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), and monoamine oxidase inhibitors (MAOIs), as well as other atypical antidepressants [3]. The choice of treatment often depends on individual patient factors, symptom severity, and response to previous therapies.
What are the potential side effects of Auvelity?
Common side effects reported for Auvelity include dizziness, headache, diarrhea, nausea, and dry mouth [1]. Serious potential side effects include an increased risk of suicidal thoughts and behaviors, particularly in children, adolescents, and young adults. The drug also carries a risk of central nervous system effects like hallucinations, delusions, and confusion. Additionally, there is a risk of hypersensitivity reactions and potential for increased blood pressure and heart rate [1].
Can Auvelity be taken with other medications?
Auvelity can interact with other medications. It is contraindicated with monoamine oxidase inhibitors (MAOIs) and should not be taken within 14 days of stopping an MAOI [1]. It also interacts with drugs that inhibit or induce CYP2D6, a liver enzyme involved in drug metabolism, as well as other medications that affect neurotransmitters [1]. Patients should inform their healthcare provider about all medications they are taking before starting Auvelity.
What is the difference between Auvelity and other antidepressants?
Auvelity's active ingredients, dextromethorphan and bupropion, offer a different pharmacological approach compared to many traditional antidepressants like SSRIs or SNRIs, which primarily target serotonin and norepinephrine [1][3]. Dextromethorphan's action on NMDA and sigma-1 receptors, combined with bupropion's dopaminergic and noradrenergic effects, distinguishes its mechanism of action [1].
What is the typical dosage of Auvelity?
The recommended starting dose for Auvelity is one tablet once daily for three days, followed by one tablet twice daily thereafter [1].
Are there clinical trials or studies on Auvelity?
Clinical trials were conducted to evaluate the safety and efficacy of Auvelity for the treatment of MDD. These studies formed the basis for its FDA approval [1].
---
Sources
1. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/217018s000lbl.pdf
2. https://drugpatentwatch.com/
3. https://www.mayoclinic.org/diseases-conditions/depression/diagnosis-treatment/drc-20356013